 MONTREAL, Nov. 06, 2020 GLOBE NEWSWIRE -- Theratechnologies Inc. Theratechnologies TSX: TH NASDAQ: THTX, a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that an oral presentation including data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease NAFLD will be given by Lindsay T Fourman, MD, of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting 2020 of the American Association for the Study of Liver Diseases AASLD to be held November 13-16, 2020. 